T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action

Publisher： Karger

E-ISSN： 1421-9832|208|4|297-306

ISSN： 1018-8665

Source： Dermatology, Vol.208, Iss.4, 2004-06, pp. : 297-306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis

By  

Dermatology, Vol. 213, Iss. 3, 2006-10 ,pp. : 204-214

Karger

Access to resources Recommend Favorite

A Comparison of Mycophenolate Mofetil with Ciclosporine for the Treatment of Chronic Plaque-Type Psoriasis

By  

Dermatology, Vol. 219, Iss. 2, 2009-06 ,pp. : 126-132

Karger

Access to resources Recommend Favorite

Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness

By  

Dermatology, Vol. 218, Iss. 2, 2008-12 ,pp. : 110-113

Karger

Access to resources Recommend Favorite

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

By  

Dermatology, Vol. 222, Iss. 3, 2011-04 ,pp. : 250-255

Karger

Access to resources Recommend Favorite

Dermatologists’ Adherence to the Guideline of the Dutch Society of Dermatology and Venereology with Respect to the Treatment with Methotrexate for Severe Chronic Plaque Psoriasis: Results from a Dutch Survey

By  

Dermatology, Vol. 215, Iss. 1, 2007-06 ,pp. : 45-52

Karger

Access to resources Recommend Favorite